{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:39:21Z","timestamp":1791301161591,"version":"4.1.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Italian Ministry of University","award":["RBIN047W33"],"award-info":[{"award-number":["RBIN047W33"]}]},{"name":"Italian Society of Pharmacology"},{"name":"Emilia-Romagna and Region Aquitaine cooperation project","award":["2255\/2010 and 2011\/2589"],"award-info":[{"award-number":["2255\/2010 and 2011\/2589"]}]},{"DOI":"10.13039\/501100006251","name":"University of Bordeaux","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006251","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004794","name":"Centre National de la Recherche Scientifique","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-12-BSV4-0001-01"],"award-info":[{"award-number":["ANR-12-BSV4-0001-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-LABX-43 to E.B."],"award-info":[{"award-number":["ANR-10-LABX-43 to E.B."]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.nbd.2016.01.016","type":"journal-article","created":{"date-parts":[[2016,1,22]],"date-time":"2016-01-22T07:30:26Z","timestamp":1453447826000},"page":"55-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Genetic and pharmacological evidence that endogenous nociceptin\/orphanin FQ contributes to dopamine cell loss in Parkinson's disease"],"prefix":"10.1016","volume":"89","author":[{"given":"Ludovico","family":"Arcuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Viaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Bido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Calcagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Olivier","family":"Fernagut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurulain T.","family":"Zaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girolamo","family":"Cal\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwan","family":"Bezard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Morari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2016.01.016_bb0005","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1474-4422(03)00432-0","article-title":"Neuroprotection for Parkinson's disease: a call for clinically driven experimental design","volume":"2","author":"Bezard","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2016.01.016_bb0010","doi-asserted-by":"crossref","first-page":"10999","DOI":"10.1523\/JNEUROSCI.23-35-10999.2003","article-title":"Enriched environment confers resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and cocaine: involvement of dopamine transporter and trophic factors","volume":"23","author":"Bezard","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2016.01.016_bb0015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/mds.25108","article-title":"Animal models of Parkinson's disease: limits and relevance to neuroprotection studies","volume":"28","author":"Bezard","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2016.01.016_bb0020","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40478-015-0222-2","article-title":"Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by alpha-synuclein overexpression","volume":"3","author":"Bourdenx","year":"2015","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.nbd.2016.01.016_bb0025","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1471-4159.2006.03902.x","article-title":"Differential protection against MPTP or methamphetamine toxicity in dopamine neurons by deletion of ppN\/OFQ expression","volume":"98","author":"Brown","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2016.01.016_bb0030","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.expneurol.2012.01.011","article-title":"Axon degeneration in Parkinson's disease","volume":"246","author":"Burke","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2016.01.016_bb0035","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/sj.bjp.0703219","article-title":"Pharmacology of nociceptin and its receptor: a novel therapeutic target","volume":"129","author":"Calo","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.nbd.2016.01.016_bb0040","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0140-6736(04)17103-1","article-title":"Alpha-synuclein locus duplication as a cause of familial Parkinson's disease","volume":"364","author":"Chartier-Harlin","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.nbd.2016.01.016_bb0045","article-title":"Nociceptin\/orphanin FQ Inhibits the survival and axon growth of midbrain dopaminergic neurons through a p38-MAPK dependent mechanism","author":"Collins","year":"2015","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.nbd.2016.01.016_bb0050","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1002\/mds.23948","article-title":"Parkinson's disease and alpha-synuclein expression","volume":"26","author":"Devine","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2016.01.016_bb0055","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.neuropharm.2008.12.009","article-title":"Alterations of N\/OFQ and NOP receptor gene expression in the substantia nigra and caudate putamen of MPP+ and 6-OHDA lesioned rats","volume":"56","author":"Di Benedetto","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nbd.2016.01.016_bb0060","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/ana.23881","article-title":"Levodopa gains psychostimulant-like properties after nigral dopaminergic loss","volume":"74","author":"Engeln","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2016.01.016_bb0065","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/sj.bjp.0707377","article-title":"Nocistatin inhibits 5-hydroxytryptamine release in the mouse neocortex via presynaptic Gi\/o protein linked pathways","volume":"152","author":"Fantin","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.nbd.2016.01.016_bb0070","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/syn.21719","article-title":"Age-related motor dysfunction and neuropathology in a transgenic mouse model of multiple system atrophy","volume":"68","author":"Fernagut","year":"2014","journal-title":"Synapse"},{"key":"10.1016\/j.nbd.2016.01.016_bb0075","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/sj.bjp.0704998","article-title":"Inhibition of striatal and retinal dopamine release via nociceptin\/orphanin FQ receptors","volume":"137","author":"Flau","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.nbd.2016.01.016_bb0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0014-2999(96)00707-8","article-title":"Nociceptin stimulates locomotion and exploratory behaviour in mice","volume":"317","author":"Florin","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.nbd.2016.01.016_bb0085","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/00001756-199702100-00025","article-title":"Orphan neuropeptide NocII, a putative pronociceptin maturation product, stimulates locomotion in mice","volume":"8","author":"Florin","year":"1997","journal-title":"Neuroreport"},{"key":"10.1016\/j.nbd.2016.01.016_bb0090","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1523\/JNEUROSCI.3309-03.2004","article-title":"Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease","volume":"24","author":"Furuya","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2016.01.016_bb0095","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.peptides.2007.04.012","article-title":"Altered anxiety-related behavior in nociceptin\/orphanin FQ receptor gene knockout mice","volume":"28","author":"Gavioli","year":"2007","journal-title":"Peptides"},{"key":"10.1016\/j.nbd.2016.01.016_bb0100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.neuroscience.2010.04.033","article-title":"MPTP treatment increases expression of pre-pro-nociceptin\/orphanin FQ mRNA in a subset of substantia nigra reticulata neurons","volume":"169","author":"Gouty","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2016.01.016_bb0105","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1046\/j.1471-4159.2003.01600.x","article-title":"Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice","volume":"84","author":"Gross","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2016.01.016_bb0110","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nprot.2006.342","article-title":"Protocol for the MPTP mouse model of Parkinson's disease","volume":"2","author":"Jackson-Lewis","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.nbd.2016.01.016_bb0115","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1124\/jpet.109.156711","article-title":"Nociceptin\/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin\/orphanin FQ\/mu-opioid receptor agonists","volume":"331","author":"Khroyan","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.nbd.2016.01.016_bb0120","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1523\/JNEUROSCI.22-07-02780.2002","article-title":"Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system","volume":"22","author":"Kirik","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2016.01.016_bb0125","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1093\/brain\/awt192","article-title":"Disease duration and the integrity of the nigrostriatal system in Parkinson's disease","volume":"136","author":"Kordower","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2016.01.016_bb0130","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/sj.bjp.0705583","article-title":"Evidence in locomotion test for the functional heterogeneity of ORL-1 receptors","volume":"141","author":"Kuzmin","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.nbd.2016.01.016_bb0135","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/nrd2572","article-title":"The nociceptin\/orphanin FQ receptor: a target with broad therapeutic potential","volume":"7","author":"Lambert","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.nbd.2016.01.016_bb0140","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1046\/j.1365-2818.1998.00365.x","article-title":"Global spatial sampling with isotropic virtual planes: estimators of length density and total length in thick, arbitrarily orientated sections","volume":"191","author":"Larsen","year":"1998","journal-title":"J. Microsc."},{"key":"10.1016\/j.nbd.2016.01.016_bb0145","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1172\/JCI9716","article-title":"Nociceptin\/orphanin FQ exacerbates excitotoxic white-matter lesions in the murine neonatal brain","volume":"107","author":"Laudenbach","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.nbd.2016.01.016_bb0150","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/70978","article-title":"Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease","volume":"5","author":"Liberatore","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2016.01.016_bb0155","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.neuroscience.2009.12.006","article-title":"Endogenous nociceptin\/orphanin FQ (N\/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naive and nociceptin\/orphanin FQ receptor knockout mice","volume":"166","author":"Mabrouk","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2016.01.016_bb0160","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/00001756-200207020-00013","article-title":"Rat ventral midbrain dopamine neurons express the orphanin FQ\/nociceptin receptor ORL-1","volume":"13","author":"Maidment","year":"2002","journal-title":"Neuroreport"},{"key":"10.1016\/j.nbd.2016.01.016_bb0165","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3389\/fncel.2013.00173","article-title":"The role of orphanin FQ\/nociceptin in neuroplasticity: relationship to stress, anxiety and neuroinflammation","volume":"7","author":"Mallimo","year":"2013","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.nbd.2016.01.016_bb0170","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0306-4522(02)00050-7","article-title":"Nociceptin\/orphanin FQ receptors modulate glutamate extracellular levels in the substantia nigra pars reticulata. A microdialysis study in the awake freely moving rat","volume":"112","author":"Marti","year":"2002","journal-title":"Neuroscience."},{"key":"10.1016\/j.nbd.2016.01.016_bb0175","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/j.1471-4159.2004.02843.x","article-title":"Blockade of nociceptin\/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release","volume":"91","author":"Marti","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2016.01.016_bb0180","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.1523\/JNEUROSCI.0987-04.2004","article-title":"Blockade of nociceptin\/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior","volume":"24","author":"Marti","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2016.01.016_bb0185","doi-asserted-by":"crossref","first-page":"9591","DOI":"10.1523\/JNEUROSCI.2546-05.2005","article-title":"Blockade of nociceptin\/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease","volume":"25","author":"Marti","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2016.01.016_bb0190","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1523\/JNEUROSCI.4346-06.2007","article-title":"The nociceptin\/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway","volume":"27","author":"Marti","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2016.01.016_bb0195","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1111\/j.1471-4159.2008.05735.x","article-title":"The novel nociceptin\/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA","volume":"107","author":"Marti","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2016.01.016_bb0200","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/mds.23271","article-title":"Brain interstitial nociceptin\/orphanin FQ levels are elevated in Parkinson's disease","volume":"25","author":"Marti","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2016.01.016_bb0205","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/j.1476-5381.2012.02219.x","article-title":"Acute and chronic antiparkinsonian effects of the novel nociceptin\/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111","volume":"168","author":"Marti","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.nbd.2016.01.016_bb0210","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3233\/JPD-2011-11023","article-title":"MPTP mouse models of Parkinson's disease: an update","volume":"1","author":"Meredith","year":"2011","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.nbd.2016.01.016_bb0215","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/377532a0","article-title":"Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor","volume":"377","author":"Meunier","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2016.01.016_bb0220","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0031-6997(24)01502-3","article-title":"The molecular and behavioral pharmacology of the orphanin FQ\/nociceptin peptide and receptor family","volume":"53","author":"Mogil","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.nbd.2016.01.016_bb0225","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2174\/187152710790966713","article-title":"The nociceptin\/orphanin FQ system as a target for treating alcoholism","volume":"9","author":"Murphy","year":"2010","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.nbd.2016.01.016_bb0230","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1471-4159.1999.0730179.x","article-title":"Orphanin FQ\/nociceptin modulation of mesolimbic dopamine transmission determined by microdialysis","volume":"73","author":"Murphy","year":"1999","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2016.01.016_bb0235","first-page":"116","article-title":"Orphanin FQ\/nociceptin suppresses motor activity through an action along the mesoaccumbens axis in rats","volume":"29","author":"Narayanan","year":"2004","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.nbd.2016.01.016_bb0240","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/(SICI)1096-9861(19991004)412:4<563::AID-CNE2>3.0.CO;2-Z","article-title":"Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: comparison of ORL1 receptor mRNA expression with (125)I-[(14)Tyr]-orphanin FQ binding","volume":"412","author":"Neal","year":"1999","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.nbd.2016.01.016_bb0245","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/(SICI)1096-9861(19990419)406:4<503::AID-CNE7>3.0.CO;2-P","article-title":"Localization of orphanin FQ (nociceptin) peptide and messenger RNA in the central nervous system of the rat","volume":"406","author":"Neal","year":"1999","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.nbd.2016.01.016_bb0250","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0891-0618(01)00135-1","article-title":"Expression of orphanin FQ and the opioid receptor-like (ORL1) receptor in the developing human and rat brain","volume":"22","author":"Neal","year":"2001","journal-title":"J. Chem. Neuroanat."},{"key":"10.1016\/j.nbd.2016.01.016_bb0255","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1093\/emboj\/16.8.1858","article-title":"Unrestrained nociceptive response and disregulation of hearing ability in mice lacking the nociceptin\/orphaninFQ receptor","volume":"16","author":"Nishi","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/j.nbd.2016.01.016_bb0260","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/cne.10154","article-title":"Nociceptin\/orphanin FQ and opioid receptor-like receptor mRNA expression in dopamine systems","volume":"444","author":"Norton","year":"2002","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.nbd.2016.01.016_bb0265","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/32660","article-title":"Nocistatin, a peptide that blocks nociceptin action in pain transmission","volume":"392","author":"Okuda-Ashitaka","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2016.01.016_bb0270","doi-asserted-by":"crossref","first-page":"10403","DOI":"10.1074\/jbc.M111.271866","article-title":"Identification of NIPSNAP1 as a nocistatin-interacting protein involving pain transmission","volume":"287","author":"Okuda-Ashitaka","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2016.01.016_bb0275","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1523\/JNEUROSCI.15-05-03863.1995","article-title":"Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test","volume":"15","author":"Olsson","year":"1995","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2016.01.016_bb0280","series-title":"The Mouse Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2001"},{"key":"10.1016\/j.nbd.2016.01.016_bb0285","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1046\/j.1471-4159.2001.00183.x","article-title":"The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety","volume":"76","author":"Przedborski","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2016.01.016_bb0290","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/ana.24066","article-title":"Lewy body extracts from Parkinson disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys","volume":"75","author":"Recasens","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2016.01.016_bb0295","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1126\/science.270.5237.792","article-title":"Orphanin-Fq - a neuropeptide that activates an opioid-like G-protein-coupled receptor","volume":"270","author":"Reinscheid","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.nbd.2016.01.016_bb0300","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1124\/jpet.106.116780","article-title":"Pharmacological characterization of the nociceptin\/orphanin FQ receptor antagonist SB-612111 [(\u2212)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrah ydro-5H-benzocyclohepten-5-ol]: in vivo studies","volume":"321","author":"Rizzi","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.nbd.2016.01.016_bb0305","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0006-8993(96)01162-6","article-title":"Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test","volume":"749","author":"Rozas","year":"1997","journal-title":"Brain Res."},{"key":"10.1016\/j.nbd.2016.01.016_bb0310","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00213-003-1643-3","article-title":"Central administration of nociceptin\/orphanin FQ blocks the acquisition of conditioned place preference to morphine and cocaine, but not conditioned place aversion to naloxone in mice","volume":"172","author":"Sakoori","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.nbd.2016.01.016_bb0315","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1037\/0735-7044.102.5.748","article-title":"The catalepsy test: its Ups and downs","volume":"102","author":"Sanberg","year":"1988","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.nbd.2016.01.016_bb0320","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0014-4886(79)90003-7","article-title":"Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of parkinsonism","volume":"64","author":"Schallert","year":"1979","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2016.01.016_bb0325","doi-asserted-by":"crossref","first-page":"34451","DOI":"10.1074\/jbc.M202099200","article-title":"The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induces apoptosis in mouse nigrostriatal glia. Relevance to nigral neuronal death and striatal neurochemical changes","volume":"277","author":"Serra","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2016.01.016_bb0330","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1124\/jpet.106.116764","article-title":"Pharmacological characterization of the nociceptin\/orphanin FQ receptor antagonist SB-612111 [(\u2212)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrah ydro-5H-benzocyclohepten-5-ol]: in vitro studies","volume":"321","author":"Spagnolo","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.nbd.2016.01.016_bb0335","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0361-9230(88)90240-7","article-title":"Time course of MPTP-induced degeneration of the nigrostriatal dopamine system in C57 BL\/6 mice","volume":"21","author":"Sundstrom","year":"1988","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.nbd.2016.01.016_bb0340","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0306-4522(96)00545-3","article-title":"In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining","volume":"77","author":"Tatton","year":"1997","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2016.01.016_bb0345","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.nbd.2006.12.021","article-title":"MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity","volume":"26","author":"Thomas","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2016.01.016_bb0350","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0079-6123(10)84005-1","article-title":"Viral vector-mediated overexpression of alpha-synuclein as a progressive model of Parkinson's disease","volume":"184","author":"Ulusoy","year":"2010","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.nbd.2016.01.016_bb0355","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.neurobiolaging.2014.11.015","article-title":"Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors","volume":"36","author":"Van der Perren","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.nbd.2016.01.016_bb0360","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.nbd.2008.02.011","article-title":"Nociceptin\/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism","volume":"30","author":"Viaro","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2016.01.016_bb0365","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.neuropharm.2013.04.046","article-title":"Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin\/orphanin FQ receptor ligands","volume":"72","author":"Viaro","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nbd.2016.01.016_bb0370","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1002\/mds.22086","article-title":"The nociceptin\/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease","volume":"23","author":"Visanji","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2016.01.016_bb0375","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1111\/j.1471-4159.2010.07061.x","article-title":"Further evidence for an involvement of nociceptin\/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice","volume":"115","author":"Volta","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2016.01.016_bb0380","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.expneurol.2010.12.024","article-title":"Dopamine-nociceptin\/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: involvement of D2\/D3 receptors and impact on nigro-thalamic neurons and motor activity","volume":"228","author":"Volta","year":"2011","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2016.01.016_bb0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cne.902960102","article-title":"Unbiased stereological estimation of the number of neurons in the human hippocampus","volume":"296","author":"West","year":"1990","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.nbd.2016.01.016_bb0390","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1471-4159.2004.02728.x","article-title":"Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease","volume":"91","author":"Yamada","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2016.01.016_bb0395","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1124\/jpet.103.055848","article-title":"Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (\u2212)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahy dro-5H-benzocyclohepten-5-ol (SB-612111)","volume":"308","author":"Zaratin","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.nbd.2016.01.016_bb0400","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/sj.gt.3300938","article-title":"Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield","volume":"6","author":"Zolotukhin","year":"1999","journal-title":"Gene Ther."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096999611630016X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096999611630016X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T06:14:20Z","timestamp":1748758460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096999611630016X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":80,"alternative-id":["S096999611630016X"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2016.01.016","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic and pharmacological evidence that endogenous nociceptin\/orphanin FQ contributes to dopamine cell loss in Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2016.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}